The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Inhibition of HMG-CoA Reductase by Atorvastatin Decreases Both VLDL and LDL Apolipoprotein B Production in Miniature Pigs
Open accessAbstract
In the present studies, the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor atorvastatin was used to test the hypothesis that inhibition of cholesterol biosynthesis in vivo with a consequent reduction in the availability of hepatic cholesterol for lipoprotein synthesis, would (1) reduce very low density lipoprotein (VLDL) apolipoprotein B (apoB) secretion into the plasma, (2) reduce the conversion of VLDL apoB to LDL apoB, and (3) reduce LDL apoB direct synthesis. ApoB kinetic studies were carried out in six control miniature pigs and in six animals after 21 days of administration of atorvastatin (3 mg/kg per day). Pigs were fed a fat- (34% of calories; polyunsaturated to monounsaturated to saturated ratio, 1:1:1) and cholesterol- (400 mg/d cholesterol; 0.1%; 0.2 mg/kcal) containing pig chow–based diet. Atorvastatin treatment significantly reduced plasma total cholesterol, LDL cholesterol, total triglyceride, and VLDL triglyceride concentrations by 16%, 31%, 19%, and 28%, respectively ( P <.01). Autologous 131 I-VLDL, 125 I-LDL, and [ 3 H]leucine were injected simultaneously into each pig, and apoB kinetic data were analyzed using multicompartmental analysis ( saam ii ). The VLDL apoB pool size decreased by 29% (0.46 versus 0.65 mg/kg; P =.002), which was entirely due to a 34% reduction in the VLDL apoB production rate (PR) (1.43 versus 2.19 mg/kg per hour; P =.027). The fractional catabolic rate (FCR) was unchanged. The LDL apoB pool size decreased by 30% (4.74 versus 6.75 mg/kg; P =.0004), which was due to a 22% reduction in the LDL apoB PR (0.236 versus 0.301 mg/kg per hour; P =.004), since the FCR was unchanged. The reduction in LDL apoB PR was primarily due to a 34% decrease in conversion of VLDL apoB to LDL apoB; however, this reduction was not statistically significant ( P =.114). Hepatic apoB mRNA abundance quantitated by RNase protection assay was decreased by 13% in the atorvastatin-treated animals ( P =.003). Hepatic and intestinal LDL receptor mRNA abundances were not affected. We conclude that inhibition of hepatic HMG-CoA reductase by atorvastatin reduces both VLDL and LDL apoB concentrations, primarily by decreasing apoB secretion into the plasma and not by an increase in hepatic LDL receptor expression. This decrease in apoB secretion may, in part, be due to a reduction in apoB mRNA abundance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
The biology of HMG-CoA reductase: the pros of contra-regulation
Hampton, R., Dimster-Denk, D., & Rine, J. (1996) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)80168-x · Cited by 147
Effects of simvastatin on apoB metabolism and LDL subfraction distribution
Gaw, A., Packard, C. J., Murray, E. F., Lindsay, G. M., Griffin, B. A., Caslake, M. J., Vallance, B. D., Lorimer, A. R., & Shepherd, J. (1993) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.13.2.170 · Cited by 104
Fast, D. G., & Vance, D. E. (1995) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00116-t · Cited by 77
Cited by
Athyros, V. G., Papageorgiou, A. A., Athyrou, V. V., Demitriadis, D. S., & Kontopoulos, A. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1198 · Cited by 257
Wilcox, L. J., Borradaile, N. M., de Dreu, L. E., & Huff, M. W. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31634-5 · Cited by 254
Self-citationForster, L. F., Stewart, G., Bedford, D., Stewart, J. P., Rogers, E., Shepherd, J., Packard, C. J., & Caslake, M. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00052-7 · Cited by 77
Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes
Ouguerram, K., Magot, T., Zäir, Y., Marchini, J. S., Charbonnel, B., Laouenan, H., & Krempf, M. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.048991 · Cited by 44
Hopkins, P. N., Nanjee, M. N., Wu, L. L., McGinty, M. G., Brinton, E. A., Hunt, S. C., & Anderson, J. L. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.05.016 · Cited by 29
Metadata
- Authors
- Burnett, J. R., Wilcox, L. J., Telford, D. E., Kleinstiver, S. J., Barrett, P. H. R., Newton, R. S., & Huff, M. W.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1997-11
- Volume
- 17
- Issue
- 11
- Pages
- 2589-2600
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2028765524
- Cited by
- 99
- References
- 4
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.